"Toll-Like Receptor 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that binds unmethylated CPG CLUSTERS. It mediates cellular responses to bacterial pathogens by distinguishing between self and bacterial DNA.
| Descriptor ID |
D051217
|
| MeSH Number(s) |
D12.776.260.750 D12.776.543.750.705.910.500.900
|
| Concept/Terms |
Toll-Like Receptor 9- Toll-Like Receptor 9
- Toll Like Receptor 9
- TLR9 Receptor
- Receptor, TLR9
- TLR9 Protein
- CD289 Antigen
- Antigen, CD289
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 9".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 9".
This graph shows the total number of publications written about "Toll-Like Receptor 9" by people in this website by year, and whether "Toll-Like Receptor 9" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 8 | 8 |
| 2005 | 0 | 10 | 10 |
| 2006 | 8 | 3 | 11 |
| 2007 | 2 | 4 | 6 |
| 2008 | 3 | 0 | 3 |
| 2009 | 5 | 5 | 10 |
| 2010 | 7 | 3 | 10 |
| 2011 | 11 | 3 | 14 |
| 2012 | 3 | 8 | 11 |
| 2013 | 5 | 4 | 9 |
| 2014 | 6 | 2 | 8 |
| 2015 | 9 | 1 | 10 |
| 2016 | 5 | 0 | 5 |
| 2017 | 7 | 2 | 9 |
| 2018 | 4 | 4 | 8 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 5 | 8 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 0 | 2 |
Below are the most recent publications written about "Toll-Like Receptor 9" by people in Profiles.
-
Defective endomembrane dynamics in Rab27a deficiency impairs nucleic acid sensing and cytokine secretion in immune cells. Cell Rep. 2024 Aug 27; 43(8):114598.
-
TLR9 Monotherapy in Immune-Competent Mice Suppresses Orthotopic Prostate Tumor Development. Cells. 2024 01 02; 13(1).
-
Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus. Clin Infect Dis. 2023 08 14; 77(3):414-418.
-
Disulfide-HMGB1 signals through TLR4 and TLR9 to induce inflammatory macrophages capable of innate-adaptive crosstalk in human liver transplantation. Am J Transplant. 2023 Dec; 23(12):1858-1871.
-
Toll-like receptor mediated inflammation directs B cells towards protective antiviral extrafollicular responses. Nat Commun. 2023 07 05; 14(1):3979.
-
Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model. Surgery. 2023 09; 174(3):666-673.
-
Nanoparticle vaccines can be designed to induce pDC support of mDCs for increased antigen display. Biomater Sci. 2023 Jan 17; 11(2):596-610.
-
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022 12 01; 28(23):5079-5087.
-
Increased macrophage phagocytic activity with TLR9 agonist conjugation of an anti- Borrelia burgdorferi monoclonal antibody. Clin Immunol. 2023 01; 246:109180.
-
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.